Low-Dose Semaglutide Treatment for Weight Loss and Heart Health in Obese Adult Pakistanis Without Type 2 Diabetes

What this Trial Is About

Researchers are evaluating the efficacy and safety of low-dose semaglutide for weight loss and cardiometabolic improvement in obese Pakistani adults without type 2 diabetes. This pilot trial is open-label, single-arm, and conducted at a single center, aiming to provide local clinical evidence to support obesity management with semaglutide in this population. The study will enroll 60 adults aged 18 years or older with a BMI of 27.5 kgm or higher and no diagnosis of type 2 diabetes confirmed by blood tests. Participants will receive once-weekly subcutaneous injections of semaglutide following a dose titration schedule 0.25 mg weekly for 4 weeks, 0.5 mg weekly for 4 weeks, and 1.0 mg weekly for 16 weeks, totaling 24 weeks of treatment. Alongside medication, all participants will receive standardized lifestyle counseling that includes a calorie-restricted diet with a 500-750 kcal daily deficit and at least 150 minutes of moderate-intensity physical activity weekly. This single-arm study does not include a placebo or comparator group. Participants will undergo clinical and laboratory assessments at baseline, 12 weeks, and 24 weeks to monitor treatment effects and safety. Researchers will measure percentage changes in body weight as the primary outcome, alongside secondary outcomes including BMI, waist circumference, blood pressure, lipid profile, liver enzymes, and quality of life. Safety will be closely monitored through continuous tracking of adverse events and drug reactions. Data analysis will use statistical methods to evaluate changes over the study period, with participant confidentiality maintained throughout.

Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults